Life Sciences Archive » June, 2025

Life Sciences - June, 2025

237 articles

• Minn. Water Co. Prevails In Retained Limit Coverage Row
• Health Data Co. Must Face Revised Investor Fraud Suit
• Abbott Hit With Genetic Privacy Suit Over Hiring Practices
• Calif. AG Asks 9th Circ. To Undo Limits On Pay-For-Delay Ban
• Pollution Exclusion Applies Without Exception, AIG Unit Says
• Ex-J&J Atty's Race Bias Suit Lacks Facts, Company Argues
• Trump Admin Must Release NIH Funds Amid Appeal
• 10th Circ. Rejects Ex-GC's Sanctions Bid Against Loeb & Loeb
• A Midyear Review: Healthcare Dealmaking Trends Of 2025
• Move Beyond Surface-Level Edits To Master Legal Writing
• Teladoc Says Investor Suit Over User Losses Is 'Illogical'
• Observations On 5 Years Of Non-Notified CFIUS Inquiries
• Justices Call For SG's Take On Skinny Label Petition
• Illumina To Buy SomaLogic For Up To $425M
• Medical AI Co. Says Rival Targeted 'Crown Jewel' Source Code
• 9th Circ. Has Muddied Waters Of Article III Pleading Standard
• Science Research Funding Cuts Blocked By Mass. Judge
• 23andMe Judge Aims For Quick Decision On Sale To Founder
• High Court Urged To Rein In FDA Oversight Of Stem Cells
• Many Foreign Firms Could Face Stricter Access To US Markets
• Fed. Circ. Revives MSN Challenge To Bausch IBS Drug Patent
• DEA Judge Backs Federal Ban On 2 Research Chemicals
• 2nd Purdue Plan Heading For Creditor Vote, Nov. Hearing
• Investor Can't Get Emergency Injunction In Sinovac Battle
• An Underused Tariff Exemption For Medical Product Importers
• PE Firm Demands FDA Docs For Defense In Deal Challenge
• NJ Court Greenlights Beasley Allen Attys In Talc Litigation
• Competing In Modern Pentathlon Makes Me A Better Lawyer
• Nose Spray Co. Sues FTC Over Substantiation Requirement
• Taxation With Representation: Latham, Paul Weiss, Covington
• Psychedelic Therapy Reform Gets Boost From Conservatives
• Justices Let E-Cig Retailers Join Challenge To FDA Prohibition
• High Court Says FCC Orders Not Above District Court Review
• Texas Judge Vacates Biden-Era HHS Abortion Privacy Rule
• J&J Hit With $8M Verdict In Multi-Exposure Talc Case
• Anavex Gets Suit Over Rett Syndrome Clinical Trials Nixed
• Sotera Investors Urge 6th Circ. To Reopen Toxic Gas Suit
• Spectrum Pharma Investors Get First OK For $16M Deal
• Psychedelics And The Law In Focus At Colo. Conference
• High Court Concurrences Signal Hard Battle For Trans Rights
• 23andMe Seeks To Ease Concerns Over Sale To Founder
• Dealmakers Eye More Crypto-Targeted SPAC Mergers
• Ex-Drug Exec Must Testify, But Keeps 5th Amendment Rights
• Ga. Court Backs Dismissal Of Hemp Farm's Drug Raid Suit
• FDA Dodges Suit Over Ozempic, Wegovy Listing
• DC Judge Restores Some Canceled COVID Grants For Now
• Prepare For Increased FDA Inspections Of Foreign Facilities
• Dorsey & Whitney Adds Patent Partner From Perkins Coie
• Law School's Missed Lessons: Teaching Yourself Legal Tech
• DC Judge Throws Out Suits Over J&J Drug Discount Audits
• Supreme Court Upholds Tennessee Transgender Care Ban
• Chinese Co. Draws Fla. AG Probe Over Health Device Security
• Cancer Diagnostics Firm, Insurer Price 2 IPOs Totaling $902M
• Novo Nordisk Settles TM Suit Against Clinic Over Compounds
• 5 Court Battles Hinging On High Court's Trans Care Ruling
• ImmunityBio's $10.5M Investor Deal Gets Final OK
• Novartis Narrows Entresto Fight With MSN, Noratech Deals
• Ga. Panel Considers New Statute In $46M Med Mal Case
• Canadian Banks Decry BioPharma's 'Abusive' Spoofing Suit
• HHS Says Trump Orders Merit Ending Trans Health Rule Case
• David Protein Avoids Court Ordered Ingredient Sale For Now
• Dexcom Faces TM Suit Over 'Stelo' Glucose Monitor Product
• FDA Unveils Voucher Program For Fast-Paced Drug Reviews
• Navigating Potential Sources Of Tariff-Related Contract Risk
• 9th Circ. Backs Class Cert. In Suit Over Diabetes Drug Risk
• Judge Hints Zantac Makers Likely Stuck With Cancer Risk Suit
• Ozempic, Wegovy Users Want NJ To Host Vision-Loss Suits
• How AI May Reshape The Future Of Adjudication
• Surgery Partners Rejects $3.3B Bain Offer, Eyes Public Growth
• Medical AI Co. Calls Rival's Suit A Ploy To Kill Competition
• Kirkland-Led Lilly Inks $1.3B Deal For Cardio Drug Co. Verve
• When Legal Advocacy Crosses The Line Into Incivility
• Doctor Will Admit Dealing Ketamine That Killed Matthew Perry
• Life Spine Accuses Ex-CEO Of Stealing Money, Trade Secrets
• Catching Up With Delaware's Chancery Court
• Monsanto Ends Roundup Cancer Case With Midtrial Settlement
• Fed. Circ. Reverses False Ad Verdict Against ThermoLife
• Ohio Tells 6th Circ. PBM Case Doesn't Target Federal Work
• Should Patent Disputes Be Filed In The ITC Or UPC?
• NJ Should Align With Federal Rule On Expert Testimony
• Hemp Farm Says $3.9M Seizure Suit Wasn't Filed Too Late
• Saul Ewing-Led Supernus Inks Up To $795M Brain Health Deal
• 2 NY Rulings May Stem Foreign Co. Derivative Suits
• King & Spalding Adds HHS Inspector General's Chief Counsel
• Mass. Judge Blocks NIH Grant Cuts, Points To 'Discrimination'
• All 50 States Agree To Purdue Pharma's $7.4B Settlement
• Justices Turn Away Merck's Bone Drug Warning Label Row
• AbbVie Sues Colo. Over State Discount Drug Law
• Stewart Releases Flood Of Discretionary Denial Decisions
• Wash. Judge Tosses IUD Suit Against Bayer For Good
• More IPO Prospects Ready To Test Market After Chime's Debut
• 23andMe Founder's $305M Bid Buys Back Co. In Ch. 11 Sale
• Injunction Sought After J&J Unit's Catheter Antitrust Loss
• Recent Reports Shed Light On Section 340B's Effectiveness
• Investor Seeks NY Court's Help In Sinovac Control Battle
• DC Circ. Urged To Reject Approval For Braille-Free Drug Label
• Ga. Medical Co. Accused Of Infringing Swedish Co.'s Patents
• Congress Should Pass IP Reform, Starting With 3 Patent Bills
• Class Standing Issues Still Murky After Justices Punt LabCorp
• 2024 Patent Litigation: A Year In Review
• AstraZeneca Inks Up To $5.3B AI Drug Deal With Chinese Firm
• When Reshoring, IP Issues Require A Strong Action Plan
• Volunteering At Schools Makes Me A Better Lawyer
• Roundup Plaintiffs' Rip Of Expert Was Off Base, Jury Hears
• Holmes Seeks 2 Year Cut, Commits To Criminal Justice Work
• Florida, Sandoz Say They've Fixed Generic Drug Price-Fix Deal
• 23andMe Ombudsman Not Confident Sale Is Lawful
• 8th Circ. Upholds Block On Minn. Generic-Drug Price Law
• 'Forum Shopping' Center Stage At 6th Circ. Drug Pricing Args
• USPTO Tells Fed. Circ. Not To Review Ruling In Xencor Case
• GlaxoSmithKline Settles Conn. Generic Zantac Suits
• These Firms Are Landing The Most PTAB Work
• Fla.-Based Med Spa Chain Files For Ch. 11 After Expansion
• 8th Circ. Stubs Out Challenge To FDA Menthol Vape Denial
• 5 Open Questions About FDA's AI-Assisted Review Plans
• Prospects And Challenges For Expert Evidence At The UPC
• Rising PTAB Filings Follow Surge In Patent Cases
• Attacks On Judicial Independence Tend To Manifest In 3 Ways
• Harvard Researcher Held By ICE Over Specimens Released
• Judiciary Committee Clears Squires For Full Senate Vote
• Greenberg Traurig Adds IP Atty From Kilpatrick In NY
• 5 Firms Guide $1.25B BioNTech, CureVac Oncology Deal
• Chancery Tags AstraZeneca Unit For $180M 'Expectation' Loss
• 9th Circ. Doubts Kleenex Ad Fight Belongs In District Court
• PTAB Issues Mixed Group Of Discretionary Denial Decisions
• RFK Jr. Picks Vaccine Critics As Part Of CDC Panel Overhaul
• IP, Health Law Scholars Object To 23andMe Ch. 11 Data Sale
• Fed. Circ. Backs PTAB Invalidation Of Agilent CRISPR Patents
• PepGen Faces Investor Suit Over Muscular Dystrophy Drug
• These Firms Are Landing The Most Patent Litigation Work
• New Patent Cases Rebound As EDTX Seals Top Venue Spot
• Vedder Price Boosts IP, Exec Compensation Teams In NY
• J&J's Beasley Allen DQ Bid Based On 'Innuendo,' Court Told
• Law School's Missed Lessons: Appreciating Civil Procedure
• Stewart's Newest Discretionary Denial Has Attys On Edge
• States Sue To Block 23andMe From Selling DNA Data In Ch. 11
• IT Co. Urges 1st Circ. To Affirm It's Blameless For Data Breach
• Ill. Judge Questions Standing In Biogen Antitrust Suit
• Ala. Judge Orders Trans Health Org. To Publish Training Vids
• House 23andMe Hearing Raises National Security Concerns
• Dog Owner Defends Tick Meds Suit Against Elanco, Retailers
• Healthcare, Tech-Focused SPAC Prices $220M IPO
• Most M&A Dealmakers Are Targeting AI Acquisitions
• Calif. Bar Exam Fiasco Shows Why Attys Must Disclose AI Use
• Ayahuasca Church Brings Religious Use Case To DC Circ.
• Merck Gets PTAB To Nix Johns Hopkins Cancer Drug Patent
• Catching Up With Delaware's Chancery Court
• Neurocrine Loses Suit Challenging Hormone Treatment Patent
• Biopharma Co. Unit Hopes To Shed Empty Facilities In Ch. 11
• Reed Smith Int'l Arbitration Pro Jumps To Bracewell In NYC
• Judge To Limit Experts in Biogen, Genentech Drug Royalty Trial
• Acadia Win On Parkinson's Drug Patent Upheld By Fed. Circ.
• RFK Jr. Fires CDC's Entire 17-Member Vaccine Advisory Panel
• Chinese Student Accused Of Smuggling Roundworms To US
• Gov't Seeks $706M Penalty In FCA Case Against Omnicare, CVS
• Edwards Can't Get Fed. Circ. To Overrule PTAB Amendments
• Investment Firm Lead Admits To Insider Trading Biotech Stock
• 5th Amendment Can't Shield Ex-Exec, Drugmakers Argue
• Fitch Even's Ex-IP Client Wants Firm's Patent Suit Tossed
• Sheppard Mullin Adds Perkins Coie IP Trio In DC, Chicago
• AI-Powered Cancer Diagnostics Firm Targets $400M IPO
• HI Gov. Eyes Veto Of Medical Pot Bill Over Privacy Concerns
• Rite Aid Gets Stay Of Appeals From Its Earlier Bankruptcy
• Legal, Compliance Heads Named In Mallinckrodt-Endo Merger
• Husch Blackwell Hires 5 Quarles & Brady Life Sciences Pros
• In 2nd Place, Va. 'Rocket Docket' Remains Old Reliable
• Masimo Fights Ex-CEO's Bid To Ax Suit Over $450M Demand
• Patent Office Leader Rejects IPRs Based On 12-Year Wait
• Circle's Smash IPO Could Pave Way For More Crypto Listings
• Justices Reject Eligibility Appeal On Telemedicine Patents
• J&J Unit's $147M Catheter Antitrust Loss Tripled To $442M
• Pharma Co. Trade Secrets Case Stays In Fla. Despite HQ Move
• Rite Aid Emphasizes It Will Pay Rent To Objecting Landlords
• Genentech Wants $18M Novartis Award Over Licenses OK'd
• Fed. Circ. Weighs Purview Over Acorda's $17M Arbitral Award
• CVS Health Can't Dodge Blame In Omnicare False Claims Suit
• Stewart Says PTAB Should 'Never' Cancel IP As A Sanction
• Parsing A Lack Of Antitrust Info-Sharing Enforcement Clarity
• What FCA Liability Looks Like In The Cybersecurity Realm
• Exelixis Escapes Cancer Drug Invalidity Bid At PTAB
• Foreign Sovereign Entities Should Heed 9th Circ. IP Ruling
• How Attorneys Can Become Change Agents For Racial Equity
• Honeywell Says 'Patent Troll' Trying To Extort Settlement
• Greenberg Traurig Adds Perkins Coie Tech Transactions Pro
• Mayer Brown Adds Partner To NY Corporate, Securities Team
• Red States Double Down On Bid To Stymie Trans Health Rule
• Latham-Led Virtual Health Startup Omada Prices $150M IPO
• Elon Musk Seeks $5B For AI Startup, Amid Other Reports
• Sens. Float Automatic Biosimilar Interchangeable Label
• 4 AGs Urge FDA To Lift Abortion Pill Restrictions
• 3rd Circ. Says Amgen Can Proceed With Subpoena In IP Suit
• CMS Guidance May Complicate Drug Pricing, Trigger Lawsuits
• Ex-Bush Admin Atty To Lead HHS Civil Rights Office
• Strategies For Litigating In The Unified Patent Court
• Running Marathons Makes Me A Better Lawyer
• High Court Drops Class Cert. Clarification Bid
• Calif. Won't Get Insulin Pricing Case Sent Back To State Court
• 23andMe, Bidders Agree To Post-Ch. 11 Auction Offer Process
• USPTO Says Study Disproves Pharma Patent Thicket Claims
• SEC Gets $1.1M Win Against Alleged Ga. Crypto Scammer
• Novo Nordisk Wants Hospital Sanctioned For Insulin Pen Suit
• House Committee Puts Intoxicating-Hemp Ban In Spending Bill
• Fed. Circ. Upholds Moderna's IP Win Over COVID Vax
• ITC Issues Import Ban In Dermatology Needle Patent Case
• Vape Cos. Urge 5th Circ. To Toss FDA Vape Marketing Rule
• Law School's Missed Lessons: Supporting A Trial Team
• Calif. Suffers Setback In Tariff Suit, But Gets Shot At 9th Circ.
• Fortrea Faces Investor Suit Over Post-Labcorp Financial Woes
• Pharma Group Can Pursue Challenge To Insulin Pricing Law
• Patent Deals Accelerate Access To Generics, Drug Group Says
• Regeneron Gets $407M After Antitrust Win Over Amgen
• 6th Circ. Denies PBMs' Privilege Claim In Opioid MDL
• Canada Customers Agree To Halt 23andMe Data Breach Suits
• Rosen, Pomerantz To Lead Seattle Biotech Class Action
• Latham Advises Atai In $390M Merger With Beckley Psytech
• Accord Urges Justices To Reject 'Crush-Resistant' Oxy IP Row
• Rocket Startup Launches $400M Deal With Wilbur Ross' SPAC
• Chinese Postdoc Accused Of Smuggling Crop-Blight Fungus
• The Law360 400: A Look At The Top 100 Firms
• Compliance Essentials To Mitigate AI Crime Enforcement Risk
• Adapting To Private Practice: From US Attorney To BigLaw
• Katten Adds 4 Ex-Kirkland Attys To Healthcare Practice
• Crowell & Moring Opens In Boston With Faber Daeufer Tie-Up
• J&J Unit May Owe Around $125M Over AI Tissue Imaging Deal
• Fed. Circ. Skeptical Applicant-Admitted Art Requires Expert
• 23andMe Founder Pushes Alternative Ch. 11 Sale
• Judge Allows Obviousness Defense At Bladder Drug Retrial
• Monthly Merger Review Snapshot
• 4 Mass. Rulings You May Have Missed In May
• Judge Denies UTC Bid To Block Liquidia's Lung Drug
• Most-Favored Nation Drug Pricing Could Shake Up US Pharma
• Allergan Entities Get Booted From Botox Patent Suit In Del.
• Foley & Lardner Opens In Nashville With 3 Holland & Knight Attys
• J&J Again Seeks To Block Beasley Allen In NJ Talc Litigation
• The Ins And Outs Of Consensual Judicial References
• Defamation Litigation Roundup: Cheetos, NASCAR, OpenAI
• High Court Rejects Bard Patent Misuse Dispute